000281816 001__ 281816
000281816 005__ 20251114102931.0
000281816 0247_ $$2doi$$a10.1002/alz.70812
000281816 0247_ $$2pmid$$apmid:41137622
000281816 0247_ $$2ISSN$$a1552-5260
000281816 0247_ $$2ISSN$$a1552-5279
000281816 037__ $$aDZNE-2025-01198
000281816 041__ $$aEnglish
000281816 082__ $$a610
000281816 1001_ $$00000-0003-3624-2784$$aWisch, Julie K$$b0
000281816 245__ $$aComparison of amyloid chronicity and EYO in autosomal dominant Alzheimer's disease.
000281816 260__ $$aHoboken, NJ$$bWiley$$c2025
000281816 3367_ $$2DRIVER$$aarticle
000281816 3367_ $$2DataCite$$aOutput Types/Journal article
000281816 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1763031333_32671
000281816 3367_ $$2BibTeX$$aARTICLE
000281816 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000281816 3367_ $$00$$2EndNote$$aJournal Article
000281816 520__ $$aPreclinical Alzheimer's disease (AD) can be described relative to biomarker positivity onset time.We estimated time from amyloid positivity (A+) using sampled iterative local approximation (SILA) in a longitudinal autosomal dominant AD (ADAD) sample (N = 379) with amyloid positron emission tomography. We compared (1) predicted age at A+ to imputed age, (2) estimated age at A+ to estimated age at symptom onset, and (3) variance in cognitive performance explained.Mean error between imputed and SILA-estimated age at A+ (N = 26) was 1.15 years. Age at A+ explained 39% of estimated years to symptom onset (EYO) variance. Time from A+ explained 19% of cognitive composite variance and 14% of Clinical Dementia Rating Sum of Boxes CDR-SB variance; EYO explained 43% and 57%, respectively.SILA estimates A+ age in ADAD with reasonably good accuracy. SILA-estimated time from A+ describes the start of pathology, but the time from A+ onset to symptoms is variable in ADAD and better described by EYO.Amyloid chronicity predicts a 14-year preclinical AD phase in ADAD. SILA accurately estimates age at A+ (MAE < 2 years). EYO outperforms chronicity in predicting symptom onset. APP mutation carriers show atypical amyloid accumulation. Chronicity models help reveal AD heterogeneity in preclinical stages.
000281816 536__ $$0G:(DE-HGF)POF4-352$$a352 - Disease Mechanisms (POF4-352)$$cPOF4-352$$fPOF IV$$x0
000281816 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000281816 650_7 $$2Other$$aAlzheimer's disease
000281816 650_7 $$2Other$$abiomarkers
000281816 650_7 $$2Other$$agenetic causes of Alzheimer's disease
000281816 650_7 $$2Other$$anumeric methods
000281816 650_7 $$2NLM Chemicals$$aBiomarkers
000281816 650_7 $$2NLM Chemicals$$aAmyloid
000281816 650_7 $$2NLM Chemicals$$aAmyloid beta-Peptides
000281816 650_2 $$2MeSH$$aHumans
000281816 650_2 $$2MeSH$$aAlzheimer Disease: genetics
000281816 650_2 $$2MeSH$$aAlzheimer Disease: diagnostic imaging
000281816 650_2 $$2MeSH$$aAlzheimer Disease: pathology
000281816 650_2 $$2MeSH$$aAlzheimer Disease: metabolism
000281816 650_2 $$2MeSH$$aMale
000281816 650_2 $$2MeSH$$aFemale
000281816 650_2 $$2MeSH$$aPositron-Emission Tomography
000281816 650_2 $$2MeSH$$aMiddle Aged
000281816 650_2 $$2MeSH$$aAge of Onset
000281816 650_2 $$2MeSH$$aLongitudinal Studies
000281816 650_2 $$2MeSH$$aAged
000281816 650_2 $$2MeSH$$aBiomarkers
000281816 650_2 $$2MeSH$$aDisease Progression
000281816 650_2 $$2MeSH$$aAmyloid: metabolism
000281816 650_2 $$2MeSH$$aAmyloid beta-Peptides: metabolism
000281816 7001_ $$aMcKay, Nicole S$$b1
000281816 7001_ $$aZammit, Matthew$$b2
000281816 7001_ $$aChristian, Bradley T$$b3
000281816 7001_ $$aSchultz, Stephanie A$$b4
000281816 7001_ $$aMillar, Peter R$$b5
000281816 7001_ $$aRyan, Natalie S$$b6
000281816 7001_ $$aCash, David M$$b7
000281816 7001_ $$aBelder, Christopher R S$$b8
000281816 7001_ $$aChrem, Patricio$$b9
000281816 7001_ $$aCruchaga, Carlos$$b10
000281816 7001_ $$aIbanez, Laura$$b11
000281816 7001_ $$0P:(DE-2719)2000010$$aJucker, Mathias$$b12$$udzne
000281816 7001_ $$aYakushev, Igor$$b13
000281816 7001_ $$aDay, Gregory S$$b14
000281816 7001_ $$aMurphy, Mei$$b15
000281816 7001_ $$aLlibre-Guerra, Jorge$$b16
000281816 7001_ $$aAguillon, David$$b17
000281816 7001_ $$aRoh, Jee Hoon$$b18
000281816 7001_ $$aXiong, Chengjie$$b19
000281816 7001_ $$aWang, Guoqiao$$b20
000281816 7001_ $$aLi, Yan$$b21
000281816 7001_ $$aSchindler, Suzanne E$$b22
000281816 7001_ $$aJack, Cliff$$b23
000281816 7001_ $$aMcDade, Eric$$b24
000281816 7001_ $$aBateman, Randall J$$b25
000281816 7001_ $$aBenzinger, Tammie L S$$b26
000281816 7001_ $$aAnces, Beau M$$b27
000281816 7001_ $$aNetwor, Dominantly Inherited Alzheimer$$b28$$eCollaboration Author
000281816 7001_ $$aBetthauser, Tobey$$b29
000281816 7001_ $$aGordon, Brian$$b30
000281816 773__ $$0PERI:(DE-600)2201940-6$$a10.1002/alz.70812$$gVol. 21, no. 10, p. e70812$$n10$$pe70812$$tAlzheimer's and dementia$$v21$$x1552-5260$$y2025
000281816 8564_ $$uhttps://pub.dzne.de/record/281816/files/DZNE-2025-01198%20SUP1.pdf
000281816 8564_ $$uhttps://pub.dzne.de/record/281816/files/DZNE-2025-01198%20SUP2.docx
000281816 8564_ $$uhttps://pub.dzne.de/record/281816/files/DZNE-2025-01198.pdf$$yOpenAccess
000281816 8564_ $$uhttps://pub.dzne.de/record/281816/files/DZNE-2025-01198%20SUP1.pdf?subformat=pdfa$$xpdfa
000281816 8564_ $$uhttps://pub.dzne.de/record/281816/files/DZNE-2025-01198%20SUP2.doc
000281816 8564_ $$uhttps://pub.dzne.de/record/281816/files/DZNE-2025-01198%20SUP2.odt
000281816 8564_ $$uhttps://pub.dzne.de/record/281816/files/DZNE-2025-01198%20SUP2.pdf
000281816 8564_ $$uhttps://pub.dzne.de/record/281816/files/DZNE-2025-01198.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000281816 909CO $$ooai:pub.dzne.de:281816$$popenaire$$popen_access$$pVDB$$pdriver$$pdnbdelivery
000281816 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2000010$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b12$$kDZNE
000281816 9131_ $$0G:(DE-HGF)POF4-352$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vDisease Mechanisms$$x0
000281816 9141_ $$y2025
000281816 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2025-01-06
000281816 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2025-01-06
000281816 915__ $$0LIC:(DE-HGF)CCBY4$$2HGFVOC$$aCreative Commons Attribution CC BY 4.0
000281816 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bALZHEIMERS DEMENT : 2022$$d2025-01-06
000281816 915__ $$0StatID:(DE-HGF)3001$$2StatID$$aDEAL Wiley$$d2025-01-06$$wger
000281816 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2025-01-06
000281816 915__ $$0StatID:(DE-HGF)9910$$2StatID$$aIF >= 10$$bALZHEIMERS DEMENT : 2022$$d2025-01-06
000281816 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2025-01-06
000281816 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000281816 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2025-01-06
000281816 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2025-01-06
000281816 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2025-01-06
000281816 9201_ $$0I:(DE-2719)1210001$$kAG Jucker$$lCell Biology of Neurological Diseases$$x0
000281816 980__ $$ajournal
000281816 980__ $$aVDB
000281816 980__ $$aUNRESTRICTED
000281816 980__ $$aI:(DE-2719)1210001
000281816 9801_ $$aFullTexts